SkinBioTherapeutics (SBTX) AI Stock Analysis

• Market Cap: £55.64M
• Dividend Yield: N/A
• Average Volume (3M): 673.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: 283.74%
• EPS Growth: 78.57%
• Country: UK
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 258,779,450
• 10 Day Avg. Volume: 831,404
• 30 Day Avg. Volume: 673,172
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: 18.00p ▲(35.85% Upside)

The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow) despite strong revenue growth and a relatively conservative balance sheet. Technicals are supportive due to positive momentum, but overbought signals temper that strength. Valuation remains challenging because losses make the P/E less meaningful and no dividend yield is available.

Positive Factors

Proprietary microbiome technology

Owning proprietary extraction and application methods for skin microbiome ingredients creates a durable product differentiation and IP foundation. This can sustain a competitive moat, justify premium positioning, and attract long-term licensing or partner deals across cosmetics and dermatology.

Strong revenue growth trajectory

Sustained high top-line growth indicates product-market fit and expanding distribution. Over 2-6 months this supports reinvestment in R&D, scale manufacturing, and commercial channels, helping the company convert early traction into a larger, more defensible market position.

Conservative leverage and capital structure

A low debt profile and healthy equity ratio provide financial flexibility to fund clinical work, product rollout, or partnerships without immediate refinancing pressure. This resilience supports long-term strategic moves and reduces solvency risk during growth phases.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flows indicate the business is not yet self-funding its growth. Over the medium term this raises reliance on external capital, risks dilution, and constrains the ability to invest in manufacturing, marketing, or clinical programs without additional financing.

Ongoing unprofitability and weak margins

Continued negative net income and EBIT margins suggest the company has not achieved sustainable unit economics. Without margin improvement, long-term profitability is uncertain, limiting returns to investors and making scaling commercially risky despite revenue growth.

Very small operating scale

A tiny workforce constrains capacity to execute complex commercialization, regulatory, and clinical plans concurrently. Over months this increases operational execution risk, heightens dependence on partners or contractors, and may slow scaling of manufacturing and distribution.

SkinBioTherapeutics Business Overview & Revenue Model

Company Description

SkinBioTherapeutics (SBTX) is a biotechnology company focused on developing innovative skincare products that harness the power of the skin microbiome. Operating in the health and beauty sector, SBTX aims to create products that not only enhance skin health but also address various dermatological issues. The company's core offerings include topical formulations designed to support skin barrier function and promote overall skin wellness, utilizing proprietary technology to extract and apply beneficial bacteria-derived ingredients.

How the Company Makes Money

SkinBioTherapeutics generates revenue primarily through the sale of its skincare products, which are marketed to both consumers and healthcare professionals. The company may leverage partnerships with established cosmetics and dermatology brands to distribute its products more effectively, creating additional revenue streams through licensing agreements or co-branding initiatives. Furthermore, SBTX may engage in research collaborations and clinical trials, potentially earning income through grants or funding from institutions interested in the therapeutic applications of its microbiome-based solutions. The company's focus on scientific validation and efficacy can also enhance marketability, thereby contributing to its earnings growth.

SkinBioTherapeutics Financial Statement Overview

Summary

SkinBioTherapeutics has shown revenue growth but continues to face significant financial challenges. The company reported substantial net losses and negative cash flows. Despite low debt levels, declining equity and unsustainable financing activities pose risks to financial stability.

Income Statement

The company has shown significant revenue growth, increasing from zero in previous years to £1.2 million in 2024. However, the gross profit margin stands at 56.5%, indicating some level of cost control. Despite this, the net profit margin is negative due to high operating expenses, resulting in a substantial net loss. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet presents a mixed picture. The debt-to-equity ratio is low at 0.28, indicating limited leverage. However, stockholders' equity has been decreasing over recent years, which is concerning. The equity ratio is 56.9%, suggesting moderate reliance on equity financing. Overall, the company's financial stability shows risk due to declining equity.

Cash Flow

Operating cash flow remains negative, though financing activities have provided cash inflows. The free cash flow is negative, indicating cash burn. The operating cash flow to net income ratio is around 0.95, showing that operational cash flows are still insufficient to cover losses. The company's cash position has been bolstered by financing activities, which is unsustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.64M	4.64M	1.21M	132.06K	74.76K	0.00
Gross Profit	2.71M	2.71M	683.04K	85.19K	45.34K	-5.05K
EBITDA	-223.19K	-196.54K	-2.72M	-2.96M	-2.95M	-1.49M
Net Income	-696.15K	-696.25K	-2.88M	-2.84M	-2.79M	-1.43M
Balance Sheet
Total Assets	12.13M	12.13M	5.22M	2.59M	3.08M	5.73M
Cash, Cash Equivalents and Short-Term Investments	4.78M	4.78M	800.90K	1.31M	1.80M	4.61M
Total Debt	993.47K	993.47K	818.74K	100.65K	127.86K	139.85K
Total Liabilities	2.71M	2.71M	2.25M	599.34K	609.61K	519.67K
Stockholders Equity	9.42M	9.42M	2.97M	1.99M	2.48M	5.22M
Cash Flow
Free Cash Flow	-1.30M	-1.30M	-2.92M	-2.81M	-2.77M	-1.67M
Operating Cash Flow	-1.30M	-1.30M	-2.73M	-2.65M	-2.67M	-1.56M
Investing Cash Flow	-1.62M	-1.62M	-2.30M	-165.28K	-96.81K	-112.31K
Financing Cash Flow	6.90M	6.90M	4.51M	2.32M	-35.12K	4.12M

SkinBioTherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SBTX, the sentiment is Positive. The current price of 13.25 is below the 20-day moving average (MA) of 15.38, below the 50-day MA of 15.74, and below the 200-day MA of 17.14, indicating a bullish trend. The MACD of 1.27 indicates Negative momentum. The RSI at 83.30 is Negative, neither overbought nor oversold. The STOCH value of 90.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SBTX.

SkinBioTherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AREC	56 Neutral	£32.47M	-3.89	-204.29%	―	3.31%	21.91%
APTA	52 Neutral	£26.30M	-6.96	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SBTX	50 Neutral	£55.64M	-65.15	-11.24%	―	283.74%	78.57%
IMM	46 Neutral	£36.70M	-8.20	-259.88%	―	―	―
OPTI	43 Neutral	£6.09M	-42.14	-2.42%	―	―	―
OBI	37 Underperform	£41.73M	-2.03	―	―	63.25%	8.94%

SkinBioTherapeutics Corporate Events

SkinBioTherapeutics Bolsters Board with New Audit Chair and CFO Promotion

SkinBioTherapeutics has strengthened its senior leadership team with the appointment of experienced non-executive director and audit specialist Alyson Levett as a non-executive director and Chair of the Audit Committee, and the promotion of Group Finance Director Emily Bertram to Chief Financial Officer and executive board member, effective 1 January 2026. The board reshuffle, which also sees former director Danielle Bekker step down from the board to remain as an external advisor, is positioned by the company as enhancing financial oversight and governance support at a time when management expects an especially active year ahead, potentially improving investor confidence and operational execution as it pursues its growth and consolidation strategy in the skin health sector.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

SkinBioTherapeutics Wins Shareholder Backing for Growth and Capital Authorities at AGM

SkinBioTherapeutics reported that all resolutions at its Annual General Meeting were passed, including the receipt of accounts, reappointment and fee-setting authority for its auditor, and broad authorities for directors to allot shares and equity securities, including on a non-pre-emptive basis and in connection with acquisitions or other capital investments. The voting outcomes, which showed strong but not unanimous support across all items, confirm shareholder backing for the company’s current governance, financing flexibility and acquisition-led growth strategy as it continues to develop and commercialise its skin health technologies across cosmetic and supplement markets.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

SkinBioTherapeutics Reaffirms Strong Growth Expectations for 2026

SkinBioTherapeutics plc announced that its trading has begun positively for the new financial year, reaffirming that its 2026 full-year revenue and adjusted EBITDA projections remain on target at £6.2 million and £0.7 million, respectively. This positive outlook reflects the company’s ongoing efforts to solidify its market position in the skincare and gut-skin health sectors, which is bolstered by its partnerships, innovative product lines, and strategic expansion initiatives.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

SkinBioTherapeutics Announces AGM and Annual Report Release

SkinBioTherapeutics plc has announced the posting of its Annual Report and Accounts for the year ending 30 June 2025, alongside the Notice of its Annual General Meeting (AGM) scheduled for 29 December 2025. The company continues to strengthen its position in the skin health industry through strategic partnerships and acquisitions, aiming to enhance its market presence and operational capabilities. This announcement underscores its commitment to transparency and growth, potentially impacting stakeholders positively by expanding its product reach and technological applications.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

SkinBioTherapeutics Reports Strong Growth and Strategic Expansion in 2025

SkinBioTherapeutics reported significant growth in its full-year results for 2025, with revenues increasing by 284% to £4.6 million, driven by direct sales and royalty revenues from its AxisBiotix™ and Dermatonics products. The company finalized a commercial agreement with Croda and launched Zenakine™ in the global cosmetics industry, while also expanding its retail presence through an exclusive agreement with Superdrug Stores plc. The acquisitions of Bio-Tech Solutions and Dermatonics have bolstered its manufacturing capabilities and financial performance, positioning the company for continued growth in the skin health industry.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

SkinBioTherapeutics Announces Executive Departure

SkinBioTherapeutics announced the departure of Simon Hewitson, the Executive Director and Chief Operating Officer, due to personal reasons. His responsibilities will be temporarily managed by CEO Stuart Ashman and Group Finance Director Emily Bertram while the company seeks a successor. This change in leadership may impact the company’s operations and strategic direction, particularly in its partnerships and acquisitions in the skin health sector.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.